SCHEMBL6071553

SCHEMBL6071553

COCCNC(=O)c1ccc2[nH]c3c(ccc4cn[nH]c43)c2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITK Q08881 2/20 0.51
FGFR1 P11362 1/20 0.48
PDGFRA P16234 1/20 0.48
FLT1 P17948 1/20 0.48
KDR P35968 1/20 0.48
TRPA1 O75762 1/20 0.46
HPGD P15428 5/20 0.46
ALDH1A1 P00352 5/20 0.46
KDM4E B2RXH2 5/20 0.46
HSD17B10 Q99714 3/20 0.46
GLA P06280 1/20 0.46
GAA P10253 1/20 0.46
MAPT P10636 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
LMNA P02545 1/20 0.43
HTT P42858 1/20 0.43
TNKS2 Q9H2K2 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6071310 0.94 ALDH1A1 (0.47) ITKFGFR1PDGFRAFLT1KDR
SCHEMBL6071272 0.88 KDM4E (0.48) ITKHPGDALDH1A1KDM4EHSD17B10
SCHEMBL6070577 0.85 KDM4E (0.55) ITKFGFR1PDGFRAFLT1KDR
SCHEMBL6070498 0.85 KDM4E (0.61) HPGDALDH1A1KDM4EHSD17B10MAPT
SCHEMBL6071307 0.84 MAOB (0.41) HPGDALDH1A1KDM4EHSD17B10GAA
SCHEMBL6071038 0.84 MAOB (0.39) HPGDALDH1A1KDM4EHSD17B10GAA
SCHEMBL6070594 0.83 MAPK1 (0.54) ITKFGFR1PDGFRAFLT1KDR
SCHEMBL6070463 0.81 IMPDH2 (0.54) ITKHPGDALDH1A1KDM4EMAPT
SCHEMBL6070991 0.81 KDM4E (0.39) HPGDALDH1A1KDM4EHSD17B10MAPT
SCHEMBL6070912 0.80 MAPK1 (0.51) GAARPS6KB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060264493-A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PFIZER ITALIA S.R.L. (IT) 2006-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264493-A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K1, MAP3K19, MAP3K20 ITK 517/4885FGFR1 1309/4885PDGFRA 1123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.